- Details
- Professor Jan Philipp Radtke joins Alicia Morgans, highlighting his EAU 2022 presentation focused on the ARASENS trial and the efficacy of darolutamide in metastatic hormone-sensitive prostate cancer. The trial's primary endpoint was overall survival, and the addition of darolutamide to standard care showed a significant benefit with a hazard ratio of 0.68. The combination increased the four-year...
|
- Details
- At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting, Bertrand Tombal presents de-escalation strategies in the management of metastatic hormone-sensitive prostate cancer (mHSPC) Biographies: Bertrand Tombal, MD, PhD, Chairman of the Department of Surgery and Professor of Urology at the Université catholique de Louvain (UCL), Cliniques universitaires Saint-Luc, Brussels,...
|
- Details
- At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting, Christopher Sweeney presents treatment intensification strategies in metastatic hormone-sensitive prostate cancer (mHSPC), focusing on triplet therapies. Biographies: Christopher Sweeney, MBBS, Professor of Medicine, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA Related Content: APCCC 2022: Treatme...
|
- Details
- At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting, Karim Fizazi presents when low-volume disease on conventional imaging becomes high-volume on next-generation imaging in mHSPC, we should treat these patients like low volume patients. Biographies: Karim Fizazi, MD, Ph.D., is a medical oncologist at Gustave Roussy, and a full professor in Oncology at the University of...
|
- Details
- At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting, Michael Hofman presents how frequently low-volume disease on conventional imaging becomes high-volume on next-generation imaging in the management of metastatic hormone-sensitive prostate cancer (mHSPC). Biographies: Michael Hofman, MBBS (Hons), FRACP, FAANMS, FICIS, Molecular Imaging & Therapeutic Nuclear Medicine,...
|
- Details
- At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting, Andrew Armstrong presents the uptake of new treatment options for mHSPC in real life, including education, access, use, and diversity. Biographies: Andrew Armstrong, MD, Professor of Medicine, Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC Related Content: APCCC 2022: The...
|
- Details
- Neal Shore joins Alicia Morgans in discussing the approval of NUBEQA® (darolutamide) in the metastatic hormone-sensitive setting in combination with docetaxel on ADT. Drs. Shore and Morgans speak about the clinical implications of this approval from a urologist's perspective. The approval was based on the overall survival data Matthew Smith presented at ASCO GU 2022 and the 32% reduction in mortal...
|
- Details
- In a conversation with Alicia Morgans, Professor Bertrand Tombal provides a synopsis of metastatic subtypes in the ARASENS trial outcomes. The ARASENS trial investigated the benefit of darolutamide by comparing ADT plus docetaxel and darolutamide versus a placebo group. Tombal and Morgans wrap up the conversation by acknowledging the pragmatic and effective treatment recommendations that resulted...
|
- Details
- Drs Charles Ryan and Alicia Morgans discuss the approval of NUBEQA® (darolutamide) tablets, for oral use for metastatic hormone-sensitive prostate cancer (mHSPC). The FDA has approved darolutamide in combination with docetaxel for adult patients with mHSPC. This regulatory decision is based on findings from the phase 3 ARASENS trial. ARASENS is a randomized phase 3 trial of darolutamide versus pla...
|
- Details
- In this conversation with Alicia Morgans, Bertrand Tombal discusses de-escalation treatment strategies in the management of metastatic hormone-sensitive prostate cancer (mHSPC). They discuss treatment optimization, and how we candefine the minimal dose or duration of a treatment to achieve similar efficacy while preserving quality of life, decreasing side effects, and decreasing resource utilizati...
|
